Regulatory Telomir seeks FDA approval for Telomir-1 to treat breast cancer Pharmaceutical Business ReviewThe IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.RegulatoryOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. RegulatoryOncologyRead full story Post navigation Previous: FDA points to liver injury with Amgen’s TavneosNext: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026